B
MYGN icon

Barings’s Myriad Genetics MYGN Stock Holding History

Barings’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-8,600
Closed -$304K – 1007
2015
Q1 		$304K Sell
8,600
-18,100
-68% -$648K 0.01% 809
2014
Q4 		$909K Sell
26,700
-27,665
-51% -$982K 0.02% 494
2014
Q3 		$2.1M Sell
54,365
-30,335
-36% -$1.13M 0.05% 293
2014
Q2 		$3.3M Buy
84,700
+54,200
+178% +$2.02M 0.1% 215
2014
Q1 		$1.04M Buy
30,500
+1,800
+6% +$55.8K 0.03% 456
2013
Q4 		$602K Buy
28,700
+8,700
+44% +$220K 0.03% 560
2013
Q3 		$470K Sell
20,000
-3,800
-16% -$108K 0.02% 635
2013
Q2 		$640K Buy
+23,800
New +$690K 0.03% 540

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barings's MYGN Position: Q2 2015 in Review

Barings sold out of Myriad Genetics (MYGN) in Q2 2015, closing a stake of 8,600 shares — an estimated $304K sold.

Barings first reported a position in MYGN in Q2 2013 and held it in 8 quarters. The position peaked at $3.3M in Q2 2014. 234 funds tracked by Wall St. Rank hold MYGN as of Q2 2015.

  • Barings reported no remaining Myriad Genetics position as of Q2 2015 after selling out during the quarter.
  • Barings sold 8,600 Myriad Genetics shares in Q2 2015, an estimated $304K.
  • Barings first reported a position in Myriad Genetics in Q2 2013 and held it in 8 quarters.
  • Barings's Myriad Genetics position peaked at $3.3M in Q2 2014.
  • 234 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2015.

Based on Barings's 13F filing for Q2 2015, filed 14 Aug 2015.